natgillin/translations-raw huggingface dataset:
crushing/tight chest pain that gets worse or that does not go away
tiskajoča bolečina/stiskanje v prsih, ki se stopnjuje oziroma ne popusti
Crusting on the edge of the eyelid
tvorba krast na robovih vek,
Cruzeiro
(polipropilen)
crying
jok
crying
jok,
Crying
jokanje
crying
jokanje,
Crying abnormal
nenormalen jok
Crying abnormal, irritability, restlessness
neobičajen jok, razdražljivost, vznemirjenost
Crying, feeling depressed, nervous or confused, lack of interest or emotion
jok, potrtost, živčnost ali zmedenost, pomanjkanje zanimanja ali občutkov,
Crying, feeling depressed, nervous or confused, lack of interest or emotion;
jok, potrtost, živčnost ali zmedenost, pomanjkanje zanimanja ali občutkov,
Crying, Insomnia, Sleep disorder
jok, nespečnost, motnje spanja
Crying, irritability
jok, razdražljivost
Crying, somnolence
jok, zaspanost
Cryopyrin-Associated Periodic Syndromes
S kriopirinom povezani periodični sindromi
cryopyrin-associated periodic syndromes (CAPS) in adults and children aged two years and older with a body weight of 7.5 kg or above.
s kriopirinom povezanih periodičnih sindromov (CAPS) pri odraslih in otrocih, starejših od dveh let, s telesno maso 7,5 kg ali več.
CRYSTAL enrolled gout patients with measurable tophi.
Študija CRYSTAL je zajela bolnike s protinom, ki so imeli merljive tofe.
crystalluria
kristalurija
Crystals may be seen as a paper-thin layer at the bottom of the bottle when it is stored upright.
Če steklenico shranjujete pokončno, se lahko na njenem dnu pojavi papirno tanka plast kristalov.
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30 50 % in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4).
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30–50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z mofetilmikofenolatom in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke mofetilmikofenolata (glejte tudi poglavje 4.4).
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30 50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4).
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30 – 50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z mofetilmikofenolatom in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke mofetilmikofenolata (glejte tudi poglavje 4.4).
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30-50% in renal transplant patients treated with CellCept and CsA compared with patients receiving sirolimus or belatacept and similar doses of CellCept (see also section 4.4).
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30–50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z zdravilom CellCept in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke zdravila CellCept (glejte tudi poglavje 4.4).
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30-50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4).
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30 – 50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z mofetilmikofenolata in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke mofetilmikofenolata (glejte tudi poglavje 4.4).
CsA interferes with MPA enterohepatic recycling, resulting in reduced MPA exposures by 30-50% in renal transplant patients treated with mycophenolate mofetil and CsA compared with patients receiving sirolimus or belatacept and similar doses of mycophenolate mofetil (see also section 4.4).
Ciklosporin A vpliva na enterohepatični obtok mikofenolne kisline in s tem zmanjša izpostavljenost mikofenolni kislini za 30 – 50 % pri bolnikih z ledvičnim presadkom, ki so bili zdravljeni z mofetilmikofenolatom in ciklosporinom A, v primerjavi z bolniki, ki so prejemali sirolimus ali belatacept in podobne odmerke mofetilmikofenolata (glejte tudi poglavje 4.4).
CSBM/week
CSBM/teden
CSF
cerebro
CSF penetration was confirmed in one patient; CSF exposure based on AUC of TMZ was approximately 30% of that in plasma, which is consistent with animal data.
Prodiranje v cerebrospinalno tekočino so potrdili pri enem bolniku; izpostavljenost cerebrospinalne tekočine na podlagi vrednosti AUC temozolomida je bila približno 30 % izpostavljenosti plazme, kar ustreza podatkom, pridobljenim pri živalih.
CSL Behring AG Wankdorfstrasse 10, 3000 Bern 22 Switzerland
CSL Behring AG Wankdorfstrasse 10, 3000 Bern 22 Švica
CSL Behring GmbH, Emil-von-Behring-Straße 76, 35041 Marburg, Germany.
CSL Behring GmbH, Emil-von-Behring-Straße 76, 35041 Marburg, Nemčija.
cSRI = serious recurrent ischaemia; RI = recurrent ischaemia; TIA = transient ischaemic attack; ATE = arterial thrombotic event.
cRPI = resna ponovna ishemija, PI = ponovna ishemija, TIA = tranzitorna ishemična ataka, ATD = arterijski trombotični dogodek.
CT Arm (chemotherapy alone):
kupina s samo kemoterapijo:
CT13 9NJ United-Kingdom
CT13 9NJ Velika Britanija
CTC a Grade
Stopnja CTCa
CTC Grade
Stopnja CTCa
CTC Grade 2
SMT stopnje 2
CTC Grade 3 or 4
SMT 3. ali 4. stopnje
CTC Grade 3 or 4
SMT stopnje 3 or 4
CTC Grade 3 or 4
topnja 3 ali 4 po splošnih merilih toksičnosti
CTC Grade 4b
SMT 4. stopnjab
CTC Grade 4b
SMT 4. stopnjeb
CTC Grade 4b
SMT stopnja 4b
CTC Grade 4b
SMT stopnje 4b
CTC Non-haematological toxicity (except for alopecia, nausea, vomiting)
nehematološka toksičnost po splošnih merilih toksičnosti (razen za alopecijo, navzejo, bruhanje)
CTC non-haematological toxicity (except for alopecia, nausea, vomiting)
SMT za nehematološka toksičnost (razen za alopecijo, slabost, bruhanje)
CTC non-haematological Toxicity (except for alopecia, nausea, vomiting)
SMT za nehematološko toksičnost (z izjemo alopecije, navzee in bruhanja)
CTCa Grade
Stopnja CTC a
CTCa Grade
Stopnja CTCa
CTCAE (version 3.0) Grade 3 hypertriglyceridaemia and angina pectoris occurred in < 1% of patients.
Pri manj kot 1% bolnikov je prišlo do hipertrigliceridemije in angine pektoris 3. stopnje po CTCAE (verzija 3.0).
CTCAE (version 3.0) Grade 4 peripheral oedema, hypokalaemia, urinary tract infection, cardiac failure and fractures occurred in < 1% of patients.
Do perifernih edemov, hipokaliemije, okužbe sečil, srčnega popuščanja in zlomov 4. stopnje po CTCAE (verzija 3.0) je prišlo pri manj kot 1% bolnikov.
CTCAE* Adverse reaction
Neželeni učinki po CTCAE
CTCAE* non-haematologic Grade 3 or Grade 4 adverse reaction; except for Grade 3 nausea and/or vomiting controlled by antiemetic therapy or diarrhoea responsive to antidiarrhoeal medicinal products
Nehematološki neželeni učinek 3. ali 4. stopnje po CTCAE*; razen navzee in/ali bruhanja 3. stopnje, ki ju lahko nadzorujete z antiemetičnim zdravljenjem, ali diareje, ki se odziva na antidiaroike.
CTCAEa Adverse reactions
Neželeni dogodki po CTCAEa
CTCAEa Grade
Stopnja CTCAEa
CTCAEc Grade
Stopnja CTCAEc
CTCAEc grade 3 (50,000 – 25,000/mm3)
stopnje 3 po CTCAEc (50.000 – 25.000/mm3)
CTCAEc grade 3 (<1,000 – 500/mm3)
stopnje 3 po CTCAEc (<1.000 – 500/mm3)
CTCAEc grade 3 (<8.0 – 6.5g/dl)
stopnje 3 po CTCAEc (<8,0 – 6,5 g/dl)
CTCAEc grade 3 (> 5x – 20 x ULN)
stopnje 3 po CTCAEc (> 5x – 20 x ZMN)
CTCAEc grade 4 (<25,000/mm3)
stopnje 4 po CTCAEc (<25.000/mm3)
CTCAEc grade 4 (<500/mm3)
stopnje 4 po CTCAEc (<500/mm3)
CTCAEc grade 4 (<6.5g/dl)
stopnje 4 po CTCAEc (<6,5 g/dl)
CTCL is a condition in which certain cells of the body’s lymph system called T-lymphocytes become cancerous and affect the skin.
CTCL je stanje, v katerem določene celice telesnega limfnega sistema, znane kot T-limfociti, postanejo rakaste in prizadenejo kožo.
CTCL is a rare type of lymphoma (cancer of the lymph tissue) where some white blood cells (T-cells) grow in the skin.
CTCL je redka vrsta limfoma (raka limfatičnega sistema), pri katerem nekatere bele krvničke (celice T) rastejo v kožo.
Ctrough
(0,74-0,86)
Ctrough
(0,97-1,07)
Ctrough
(1,03-1,37)
Ctrough
ombitasvir/paritap
Ctrough
paritaprevirjem,
Ctrough
ponavljati kontrole
Ctrough
verapamil
Ctrough (µg/ml)
Cmin d.r.
Ctrough values are not presented in the table because they are not available from all studies
Vrednosti Cpred naslednjim odmerkom v preglednici niso predstavljene, ker niso na voljo za vse študije
CU apsule content:
Vsebina kapsule:
Cubicin
Zdravilo Cubicin
Cubicin 350 mg powder for solution for injection or infusion
Cubicin 350 mg prašek za raztopino za injiciranje ali infundiranje
Cubicin 500 mg powder for solution for injection or infusion
Cubicin 500 mg prašek za raztopino za injiciranje ali infundiranje
Cubicin given as 2-minute intravenous injection
Zdravilo Cubicin za vnos z 2-minutno intravensko injekcijo
Cubicin given as 2-minute intravenous injection (adult patients only)
Zdravilo Cubicin za vnos z 2-minutno intravensko injekcijo (samo za odrasle bolnike)
Cubicin given as 30 or 60-minute intravenous infusion
Zdravilo Cubicin za vnos s 30- oziroma 60-minutno intravensko infuzijo
Cubicin has no known effects on the ability to drive or use machines.
Pri zdravilu Cubicin ni znanih učinkov na sposobnost upravljanja vozil in strojev.
Cubicin infusions have been studied in two large studies involving 1,118 adults with complicated skin and soft tissue infections (mainly wound infections and major abscesses) and in one study involving 246 adults with bacteraemia caused by S. aureus, including 35 who also had right-sided infective endocarditis.
Infuzije zdravila Cubicin so proučevali v dveh velikih študijah, v katerih je sodelovalo 1 118 odraslih bolnikov z zapletenimi oblikami okužbe kože in mehkih tkiv (predvsem okužbami ran in večjimi ognojki), ter v eni študiji z 246 odraslimi bolniki z bakteremijo, ki jo je povzročila bakterija S. aureus, od katerih jih je 35 imelo infektivni endokarditis desne strani.
Cubicin is a powder that is made up into a solution for injection or infusion (drip) into a vein.
Zdravilo Cubicin je prašek za pripravo raztopine za injiciranje ali infundiranje (kapalne infuzije) v veno.
Cubicin is administered intravenously in 0.9 % sodium chloride (see section 6.6).
Zdravilo Cubicin se daje v obliki intravenske infuzije v 0,9-odstotni raztopini natrijevega klorida (glejte poglavje 6.6).
Cubicin is indicated for the treatment of the following infections (see sections 4.4 and 5.1).
Zdravilo Cubicin je indicirano za zdravljenje naslednjih okužb (glejte poglavji 4.4 in 5.1):
Cubicin is not usually given to pregnant women.
Zdravila Cubicin navadno ne dajemo nosečnicam.
Cubicin is used in adults and in children and adolescents (age from 1 to 17 years) to treat infections of the skin and the tissues below the skin.
Zdravilo Cubicin uporabljamo pri odraslih in otrocih ter mladostnikih (starih od 1 do 17 let) za zdravljenje okužb kože in tkiv pod kožo.
Cubicin is used to treat the following bacterial infections:
Zdravilo Cubicin se uporablja za zdravljenje naslednjih bakterijskih okužb:
Cubicin powder for solution for injection or infusion is supplied as a pale yellow to light brown cake or powder in a glass vial.
Zdravilo Cubicin prašek za raztopino za injiciranje ali infundiranje je na voljo v obliki pogače ali prašeka bledo rumene do svetlo rjave barve v stekleni viali.
Cubicin should be discontinued in the presence of unexplained muscle symptoms if the CPK level reaches greater than 5 times upper limit of normal.
Z uporabo zdravila Cubicin je treba v prisotnosti nepojasnjenih simptomov v mišicah prenehati, če raven CPK preseže 5-kratnik zgornje meje normale.
Cubicin should not be administered to children below one year of age as studies in animals have indicated that this age group may experience severe side effects.
Zdravila Cubicin se ne sme odmerjati otrokom, ki so stari manj kot 1 leto, ker rezultati študij na živalih kažejo na možnost hudih neželenih učinkov v tej starostni skupini.
Cubicin should not be administered to patients who are taking other medicinal products associated with myopathy unless it is considered that the benefit to the patient outweighs the risk.
Zdravila Cubicin ne smemo dajati bolnikom, ki jemljejo druga zdravila, povezana z nastankom miopatij, razen če menimo, da je korist za bolnika večja od tveganja.
Cubicin should not be given more than once a day.
Zdravilo Cubicin se ne sme dati več kot enkrat na dan.
Cubicin should only be used in patients who have problems with their kidneys if the benefit of treatment is greater than its potential risk, in which case it may need to be given less often.
Zdravilo Cubicin se pri bolnikih, ki imajo težave z ledvicami, uporablja samo, če so koristi zdravljenja večje od možnih tveganj, pri čemer pa se uporablja manj pogosto.
Cubicin vials are for single-use only.
Viale z zdravilom Cubicin so namenjene samo za enkratno uporabo.
Cubicin was as effective as the standard treatments.
Zdravilo Cubicin je bilo enako učinkovito kot standardno zdravljenje.
Culture confirmed cases for serotypes 1, 4, 6B, 7F, 9V, 14, 18C, 19F and 23F contributed to the analysis.
K analizi so prispevali s kulturo potrjeni primeri serotipov 1, 4, 6B, 7F, 9V, 14, 18C, 19F in 23F.
Culture-negative fever following treatment with cladribine occurs in 10-40% of patients with hairy cell leukaemia and is rarely observed in patients with other neoplastic disorders.
Zvišana telesna temperatura z negativnimi kulturami po zdravljenju s kladribinom se pojavlja pri 10– 40 % bolnikov z dlakavocelično levkemijo in jo le redko opažamo pri bolnikih z drugimi neoplastičnimi motnjami.
Cumulativ e Nominal Recurrenc e Rate (%)c
Delež skupne nominalne ponovitve (%)c
Cumulative Cytogenetic Responsea
kumulativni citogenetični odziva
Cumulative doses ranged from 20 mg up to 60 mg.
Kumulativni odmerki so znašali od 20 mg do 60 mg.
Cumulative HBeAg seroconversion rates (%)
kumulativna stopnja HBeAg serokonverzije (%)
Cumulative Incidence of MR4
kumulativna incidenca molekularnega odziva za 4 log
Cumulative interim report by Q4 2017
Predložitev kumulativnega vmesnega poročila do 4. četrtletja 2017.
Cumulative intermediate analyses – annually.
Kumulativne vmesne analize – letno
Cumulative probability of:
Skupna verjetnost:
Cumulative rates of fluid retention and diarrhoea were 39% and 22%, respectively.
Kumulativni delež zastajanja tekočin je znašal 39%, kumulativni delež driske pa 22%.
Cumulative rates of selected adverse reactions that were reported in the 100 mg once daily recommended starting dose are shown in Table 3a.
Kumulativni deleži izbranih neželenih učinkov, o katerih so poročali pri uporabi priporočenega začetnega odmerka 100 mg enkrat na dan, so prikazani v preglednici 3a.
Cumulative resistance rates at year 4 were 22.3% for HBeAg-positive patients and 16.0% for HBeAg- negative patients in this analysis.
Pri tej analizi so bili kumulativni deleži rezistence v 4. letu 22,3% pri HBeAg- pozitivnih bolnikih in 16,0% pri HBeAg-negativnih bolnikih.
Cumulative review of the data for cytomegalovirus infection, hepatitis B, herpes simplex, herpes zoster and tuberculosis has revealed cases of reactivation of cytomegalovirus infection and hepatitis B. Evaluation of further safety reports of cytomegalovirus infection revealed that also primary in addition to reactivated cytomegalovirus infections cannot be ruled out.
Skupni pregled podatkov glede okužbe s citomegalovirusom, hepatitisa B, herpesa simplexa, herpesa zostra in tuberkuloze je pokazal primere reaktivacije okužbe s citomegalovirusom in hepatitisa B. Ocena nadaljnjih varnostnih poročil o okužbi s citomegalovirusom je pokazala, da poleg reaktivacije ne more biti izključena niti primarna okužba s citomegalovirusom.
Cumulative risk at 18 months (%)
Kumulativna ogroženost po 18 mesecih (%)
Cumulatively 119 post-marketing cases of pallor and skin discolouration have been reported.
Skupaj so v obdobju trženja poročali o 119 primerih bledice in spremenjene barve kože.
Cumulatively, 155 cases of acute kidney injury and 141 cases of renal failure, including 111 cases (32.5%) with a fatal outcome were reported.
Vsega skupaj je bilo opisanih 155 primerov akutne odpovedi ledvic in 141 primerov odpovedi ledvic, vključno s 111 primeri (32,5 %) s smrtnim izidom.
Cumulatively, 24 (7 serious and 17 non-serious) events of ‘night blindness’ in 21 spontaneous cases have been received.
Kumulativno je bilo prejetih 24 (7 resnih in 17, ki niso bili ocenjeni kot resni) dogodkov ‘nočna slepota’ in 21 spontanih primerov.
Cumulatively, 29 spontaneous cases with 48 events of ‘visual symptoms perceived in the fellow eye’ have been received.
Kumulativno je bilo prejetih 29 spontanih primerov z 48 dogodki ‘simptomi, povezani z vidom, ki so jih opazili v sosednjem očesu’.
Cumulatively, since the granting of the marketing authorisation up to the data lock- point (DLP) of the current PSUR, a total of 527 reported post-marketing cases of hypersensitivity reactions of which more than 50 % were serious including life threatening allergic reactions (264 serious, 263 non-serious).
Kumulativno so od pridobitve dovoljenja za promet z zdravilom do datum zaključka zbiranja podatkov trenutnega PSUR poročali o skupaj 527 primerih preobčutljivnostih iz obdobja trženja zdravila, med katerimi je bilo več kot 50 % resnih, vključno z življenjsko nevarnimi alergijskimi reakcijami (264 resnih, 263 primerov, ki niso bili resni).
Cumulatively, there are 29 spontaneous cases of ‘pupillary reflex impaired’ (26 serious) and 9 cases from non-interventional studies and clinical trials (4 serious).
Kumulativno obstaja 29 spontanih primerov ‘zmanjšan pupilarni refleks’ (26 resnih) in 9 primerov iz neintervencijskih študij ter kliničnih preskušanj (4 resni).
Cumulatively, there are three reported cases of myocarditis in patients receiving trametinib in combination with dabrafenib.
Skupno so pri bolnikih, ki so prejemali trametinib v kombinaciji z dabrafenibom, poročali o treh primerih miokarditisa.
Cumulatively, there have been a total of 24 case reports (all were assessed as serious) referring to 22 events of sepsis (one wound sepsis and one urosepsis), of which five were with fatal outcome and one life- threatening sepsis.
Kumulativno je bilo skupno 24 poročil o posameznih primerih (vsi so bili ocenjeni kot resni), ki se nanašajo na 22 dogodkov sepse (ena sepsa je bila posledica rane, in ena urosepsa), med katerimi jih je bilo pet s smrtnim izidom in ena življenjsko ogrožajoča sepsa.
Cumulatively, there were 4 patients who experienced a viremic episode (HBV DNA>400 copies/ml) at their last timepoint on TDF.
Kumulativno so bili 4 bolniki, ki so imeli viremično epizodo (HBV DNA > 400 kopij/ml) ob zadnji časovni točki zdravljeni z dizoproksiltenofovirijevim fumaratom.
Cup
5.000
Cup
Vsebnik
Cuprymina 925 MBq/mL radiopharmaceutical precursor, solution
Cuprymina 925 MBq/ml radiofarmacevtski predhodnik, raztopina
Cuprymina copper (64Cu) chloride
Cuprymina bakrov (64Cu) klorid
Cuprymina is a radiopharmaceutical precursor.
Cuprymina je radiofarmacevtski predhodnik.
Cuprymina is a sterile solution.
Radiofarmacevtski predhodnik Cuprymina je sterilna raztopina.
Cuprymina is a type of product called a radiopharmaceutical precursor.
Cuprymina je vrsta izdelka, imenovanega radiofarmacevtski predhodnik.
Cuprymina is contraindicated in the following cases:
Radiofarmacevtski predhodnik Cuprymina je kontraindiciran v naslednjih primerih:
Cuprymina is intended for in vitro radiolabelling of medicinal products, which are subsequently administered by the approved route.
Radiofarmacevtski predhodnik Cuprymina je namenjen za in vitro radioaktivno označevanje zdravil, ki se nato dajejo v skladu z odobreno potjo uporabe.
Cuprymina is not a medicine and it is not intended to be used on its own.
Cuprymina ni zdravilo in ni namenjeno samostojni uporabi.
Cuprymina is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates.
Radiofarmacevtski predhodnik Cuprymina se ne sme dajati neposredno bolniku, temveč ga je treba uporabiti za radioaktivno označevanje nosilnih molekul, kot so monoklonska protitelesa, peptidi ali drugi substrati.
Cuprymina is presented as a sterile, clear, and colourless solution filled in a 10 mL vial.
Cuprymina je sterilna, bistra in brezbarvna raztopina v 10-mililitrski viali.
Cuprymina is stored under the responsibility of the specialist in appropriate premises.
Radiofarmacevtski predhodnik Cuprymina se shranjuje v pristojnosti strokovnjaka v za to ustreznih prostorih.
Cuprymina is used for radiolabelling, a technique in which a substance is tagged (radiolabelled) with a radioactive compound.
Cuprymina se uporablja za radioaktivno označevanje, tehniko, pri kateri se učinkovina označi z radioaktivno snovjo.
Cuprymina is used to label certain medicines that have been specially developed for use with the active substance copper (64Cu) chloride.
Radiofarmacevtski predhodnik Cuprymina se uporablja za označevanje nekaterih zdravil, ki so bila razvita posebej za uporabo z zdravilno učinkovino bakrovega (64Cu) klorida.
Cuprymina must not be used after the expiry date and time which are stated on the label after EXP.
Radiofarmacevtskega predhodnika Cuprymina ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake EXP.
Cuprymina should not be administered directly to the patient.
Radiofarmacevtski predhodnik Cuprymina se ne sme dajati neposredno bolniku.
Cuprymina will be stored in the original package that provides protection from radiation.
Radiofarmacevtski predhodnik Cuprymina bo shranjen v originalni ovojnini, ki ščiti pred sevanjem.
Cups may contain 3 spheres to up to 400 spheres depending on the required dosages and production yields.
Merice lahko vsebujejo tri kroglice do 400 kroglic, odvisno od potrebnega odmerjanja in proizvodnih izplenov.
Curfew Bell Road Chertsey, Surrey KT16 9FG United Kingdom
Curfew Bell Road Chertsey, Surrey KT16 9FG Velika Britanija
Current available data are described in section 5.2, but no recommendation on a posology can be made.
Trenutno razpoložljivi podatki so opisani v poglavju 5.2, vendar pa priporočil za odmerjanje ne moremo podati.
Current bladder cancer or a history of bladder cancer
raku mehurja ali raku mehurja v anamnezi
Current bladder cancer or a history of bladder cancer
raku sečnega mehurja ali raku sečnega mehurja v anamnezi;
Current bladder cancer or a history of bladder cancer (see section 4.4)
Trenutni rak sečnega mehurja ali rak sečnega mehurja v anamnezi (glejte poglavje 4.4).
current bladder cancer or a history of bladder cancer uninvestigated macroscopic haematuria
z rakom mehurja ali rakom mehurja v anamnezi z neraziskano makroskopskao hematurijo
current bladder cancer or a history of bladder cancer uninvestigated macroscopic haematuria
z rakom mehurja ali rakom mehurja v anamnezi z neraziskano makroskopsko hematurijo
current bladder cancer or a history of bladder cancer uninvestigated macroscopic haematuria.
rak sečnega mehurja trenutno ali v anamnezi neraziskana makroskopska hematurija.
current bladder cancer or a history of bladder cancer, uninvestigated macroscopic haematuria.
z rakom mehurja ali rakom mehurja v anamnezi, z neraziskano makroskopsko hematurijo.
Current Cycle Next Cycle
Trenutni cikel Naslednji cikel